Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI

We characterized population-level cancer-specific outcomes for prostate cancer patients based on use of prebiopsy prostate MRI.Using SEER-Medicare claims, we identified men diagnosed with localized prostate cancer from 2010-2015 and prostate-specific antigen (PSA) < 20 ng/mL. Primary exposure was prebiopsy prostate MRI prior to diagnosis (i.e., CPT 72197 linked to urology-specific diagnosis). Outcomes included diagnosis of Grade Group 2+ disease...